Advertisement

Molecular Insight Pharmaceuticals Inc. has again had a waiver agreement extended with its bond holders, enabling company discussions associated with debt restructuring to continue. It is the the eleventh such waiver extension and will last until Oct. 15.

The Cambridge biotechnology firm noted in a press release that it plans to review debt restructuring proposals with its bond holders during the extension period.

SOURCE

Advertisement
Advertisement